Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsDowngradesPrice Target
Cantor Fitzgerald analyst Kristen Kluska downgrades Monopar Therapeutics (NASDAQ:MNPR) from Overweight to Neutral and raises the price target from $109 to $119.
Cantor Fitzgerald analyst Kristen Kluska downgrades Monopar Therapeutics (NASDAQ:MNPR) from Overweight to Neutral and raises the price target from $109 to $119.